Journal
JOURNAL OF GENERAL VIROLOGY
Volume 92, Issue -, Pages 1493-1499Publisher
MICROBIOLOGY SOC
DOI: 10.1099/vir.0.030601-0
Keywords
-
Categories
Funding
- National Institutes of Health, NIAID, DMID [U01 AI066734]
- National Center for Research Resources [1 UL1 RR024153]
- Medical Research Council [G0401610] Funding Source: researchfish
- MRC [G0401610] Funding Source: UKRI
Ask authors/readers for more resources
The prophylactic use of topical antiviral agents has recently been validated by the reduction in human immunodeficiency virus (HIV) type 1 infection incidence seen using tonofovir-containing microbicides. In order to develop a wide-spectrum microbicide to prevent infection with a wide range of sexually transmitted viruses, we have previously reported the development of HIV-neutralizing aptamers and here report the isolation and characterization of aptamers that neutralize herpes simplex virus type 2 (HSV-2). These aptamers bind the envelope glycoprotein (gD), are potent (IC50 of 20-50 nM) and are able to block infection pathways dependent on both major entry receptors, Nectin1 and HVEM. Structural analysis and mutagenesis of these aptamers reveal a core specificity element that could provide the basis for pharmaceutical development. As HSV-2 is a major risk factor for the acquisition of HIV-1, a microbicide capable of preventing HSV-2 infection would not only reduce the morbidity associated with HSV-2, but also that derived from HIV-1.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available